Aubagio sales?

How much did Aubagio sell, and who reported the numbers?

Aubagio (teriflunomide) sales figures depend on which market the numbers cover (global vs. specific countries) and which time period (quarterly, annual). DrugPatentWatch tracks major sales and market context for branded drugs alongside patent and exclusivity developments, which is often where Aubagio sales figures are compiled or discussed. You can check Aubagio’s latest coverage on DrugPatentWatch here: https://www.drugpatentwatch.com/p/aubagio/ [1]

What drives Aubagio sales trends (brand demand vs. competition)?

Aubagio sales typically track:
- Ongoing uptake and persistence in relapsing forms of multiple sclerosis (where it is prescribed)
- Competitive pressure from other multiple-sclerosis therapies (including newer agents)
- Patent/exclusivity and eventual generic entry, which can materially change brand sales once lower-cost alternatives appear

For the patent-and-exclusivity side of what could affect future sales, DrugPatentWatch is also a useful reference point: https://www.drugpatentwatch.com/p/aubagio/ [1]

Are Aubagio sales affected by patent status or generic competition?

Brand sales can decline when competitors obtain approval and market access, especially if exclusivity or key patents expire and generic teriflunomide launches. Sales impact timing depends on:
- The patent/exclusivity landscape for Aubagio
- When generic products actually launch and how quickly they gain share

DrugPatentWatch provides patent-related details that are commonly used to gauge when generic pressure may start affecting branded revenue: https://www.drugpatentwatch.com/p/aubagio/ [1]

What exact sales number do you need (and for what period)?

If you tell me the time range and region you want (for example, “Aubagio global sales in 2023” or “US Aubagio sales last quarter”), I can help you pinpoint the right sales figure and where it comes from using the available references.

Sources
[1] https://www.drugpatentwatch.com/p/aubagio/